Taking part in a clinical trial may be the best treatment choice for some essential thrombocythemia (ET) patients. Today's standard treatments for cancer are based on earlier clinical trials. LLS continues to invest funds in MPN research.
Clinical trials can involve new drugs, new combinations of drugs or approved drugs being studied to treat patients in new ways such as new drug doses or new schedules to administer the drugs. Clinical trials are conducted worldwide under rigorous guidelines to help doctors find out whether new cancer treatments are safe and effective or better than the standard treatment.
Current ET Research and Clinical Trials
Some examples of treatments being studied include:
- Possible genetic origin of MPNs. There is a theory that MPNs may occur in families; if so, they are a group of genetic diseases passed on from one generation to another. This idea is being studied to discover if abnormal genes cause MPNs.
- SAR302503. This Janus kinase inhibitor, given by mouth, is being evaluated to find the efficacy and safety of daily oral doses in patients who are resistant to or intolerant of hydroxyurea.